A. Society, Cancer facts & figures, Atlanta, 2007.

J. Chan, M. Zhang, J. Hu, J. Shin, K. Osann et al., Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States, Journal of Surgical Oncology, vol.40, issue.2, pp.103-110, 2008.
DOI : 10.1002/jso.20932

A. Dzionek, A. Fuchs, P. Schmidt, S. Cremer, M. Zysk et al., BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood, The Journal of Immunology, vol.165, issue.11, pp.6037-6083, 2000.
DOI : 10.4049/jimmunol.165.11.6037

M. Cella, D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon, Nat Med, vol.5, pp.919-942, 1999.

H. Yoneyama, K. Matsuno, Y. Zhang, T. Nishiwaki, M. Kitabatake et al., Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules, International Immunology, vol.16, issue.7, pp.915-943, 2004.
DOI : 10.1093/intimm/dxh093

F. Siegal, N. Kadowaki, M. Shodell, P. Fitzgerald-bocarsly, K. Shah et al., The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood, Science, vol.284, issue.5421, pp.1835-1842, 1999.
DOI : 10.1126/science.284.5421.1835

Y. Liu, IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors, Annual Review of Immunology, vol.23, issue.1, pp.275-306, 2005.
DOI : 10.1146/annurev.immunol.23.021704.115633

A. Kamath, C. Sheasby, and D. Tough, Dendritic Cells and NK Cells Stimulate Bystander T Cell Activation in Response to TLR Agonists through Secretion of IFN-???? and IFN-??, The Journal of Immunology, vol.174, issue.2, pp.767-76, 2005.
DOI : 10.4049/jimmunol.174.2.767

G. Jego, A. Palucka, J. Blanck, C. Chalouni, V. Pascual et al., Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation through Type I Interferon and Interleukin 6, Immunity, vol.19, issue.2, pp.225-259, 2003.
DOI : 10.1016/S1074-7613(03)00208-5

A. Goubier, B. Dubois, H. Gheit, G. Joubert, F. Villard-truc et al., Plasmacytoid Dendritic Cells Mediate Oral Tolerance, Immunity, vol.29, issue.3, pp.464-75, 2008.
DOI : 10.1016/j.immuni.2008.06.017

H. De-heer, H. Hammad, T. Soullie, D. Hijdra, N. Vos et al., Essential Role of Lung Plasmacytoid Dendritic Cells in Preventing Asthmatic Reactions to Harmless Inhaled Antigen, The Journal of Experimental Medicine, vol.161, issue.1, pp.89-98, 2004.
DOI : 10.1046/j.1365-2222.2003.01649.x

V. Sisirak, S. Renaudineau, C. Menetrier-caux, C. Aspord, J. Banchereau et al., Breast carcinoma environment inhibits human plasmacytoid dendritic cells functions, the 10th International Symposium on Dendritic Cells, 2008.

W. Zou, V. Machelon, A. Coulomb-l-'hermin, J. Borvak, F. Nome et al., Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells, Nature Medicine, vol.7, issue.12, pp.1339-1385, 2001.
DOI : 10.1038/nm1201-1339

W. Vermi, R. Bonecchi, F. Facchetti, D. Bianchi, S. Sozzani et al., Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas, The Journal of Pathology, vol.74, issue.2, pp.255-68, 2003.
DOI : 10.1002/path.1344

E. Hartmann, B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch et al., Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer, Cancer Res, vol.63, pp.6478-87, 2003.

I. Treilleux, J. Blay, N. Bendriss-vermare, I. Ray-coquard, T. Bachelot et al., Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer, Clinical Cancer Research, vol.10, issue.22, pp.7466-74, 2004.
DOI : 10.1158/1078-0432.CCR-04-0684

J. K. Chan, M. Zhang, J. M. Hu, J. Y. Shin, K. Osann et al., Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States, Journal of Surgical Oncology, vol.40, issue.2, pp.103-107, 2008.
DOI : 10.1002/jso.20932

L. Zhang, J. R. Conejo-garcia, D. Katsaros, P. A. Gimotty, M. Massobrio et al., Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer, New England Journal of Medicine, vol.348, issue.3, pp.203-213, 2003.
DOI : 10.1056/NEJMoa020177

S. Sakaguchi, Regulatory T cells ??? a brief history and perspective, European Journal of Immunology, vol.25, issue.S1, pp.3-17
DOI : 10.1002/eji.200737593

W. Zou, Regulatory T cells, tumour immunity and immunotherapy, Nature Reviews Immunology, vol.306, issue.4, pp.295-307, 2006.
DOI : 10.1038/nri1806

T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nature Medicine, vol.165, issue.9, pp.942-949, 2004.
DOI : 10.1016/S0022-1759(01)00359-3

D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet et al., The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer, Clinical Cancer Research, vol.11, issue.23, pp.8326-8331, 2005.
DOI : 10.1158/1078-0432.CCR-05-1244

K. Milne, M. Kobel, S. E. Kalloger, R. O. Barnes, D. Gao et al., Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells, DR, C. Regression model and lifer tables Ray-Coquard, I., and Pfisterer, J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, pp.449-459, 1972.

I. Vergote, C. G. Trope, F. Amant, G. B. Kristensen, T. Ehlen et al., Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, pp.943-953
DOI : 10.1056/NEJMoa0908806

D. S. Chi, E. L. Eisenhauer, J. Lang, J. Huh, L. Haddad et al., What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer, 21. Erdman, S. E. and Poutahidis, T. Roles for inflammation and regulatory T cells in colon cancer, pp.559-564, 2003.

M. Almeida, M. Cordero, J. Almeida, and A. Orfao, Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection, Aids, vol.19, pp.261-271, 2005.

T. Alvaro, M. Lejeune, M. T. Salvado, C. Lopez, J. Jaen et al., Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients, Journal of Clinical Oncology, vol.24, issue.34, pp.5350-5357, 2006.
DOI : 10.1200/JCO.2006.06.4766

C. Badoual, S. Hans, J. Rodriguez, S. Peyrard, C. Klein et al., Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers, Clinical Cancer Research, vol.12, issue.2, pp.465-472, 2006.
DOI : 10.1158/1078-0432.CCR-05-1886

C. Baecher-allan, J. A. Brown, G. J. Freeman, and D. A. Hafler, CD4+CD25high Regulatory Cells in Human Peripheral Blood, The Journal of Immunology, vol.167, issue.3, pp.1245-1253, 2001.
DOI : 10.4049/jimmunol.167.3.1245

F. Balkwill, C. , and L. M. , Cancer: An inflammatory link, Nature, vol.2, issue.7007, pp.405-406, 2004.
DOI : 10.1016/S1470-2045(03)01196-3

A. Bamias, V. Koutsoukou, E. Terpos, M. L. Tsiatas, C. Liakos et al., Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNF?? in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy, Gynecologic Oncology, vol.108, issue.2, pp.421-427, 2008.
DOI : 10.1016/j.ygyno.2007.10.018

J. C. Barnett, S. M. Bean, R. S. Whitaker, E. Kondoh, T. Baba et al., Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype, Gynecologic Oncology, vol.116, issue.3, pp.556-562
DOI : 10.1016/j.ygyno.2009.11.020

F. J. Barrat, T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu et al., Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus, The Journal of Experimental Medicine, vol.32, issue.8, pp.1131-1139, 2005.
DOI : 10.4049/jimmunol.171.6.3296

I. Bekeredjian-ding, M. Schafer, E. Hartmann, R. Pries, M. Parcina et al., and transforming growth factor-?? synergize to inhibit plasmacytoid dendritic cell-derived interferon-??, Immunology, vol.279, issue.Suppl 1, pp.439-450, 2009.
DOI : 10.1111/j.1365-2567.2009.03134.x

J. S. Berek, M. Markman, J. A. Blessing, P. R. Kucera, B. E. Nelson et al., Intraperitoneal ??-Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study, Gynecologic Oncology, vol.74, issue.1, pp.48-52, 1999.
DOI : 10.1006/gyno.1999.5455

J. S. Berek, M. Markman, B. Stonebraker, S. S. Lentz, M. D. Adelson et al., Intraperitoneal Interferon-?? in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study, Gynecologic Oncology, vol.75, issue.1, pp.10-14, 1999.
DOI : 10.1006/gyno.1999.5532

C. A. Biron, Interferons ?? and ?? as Immune Regulators???A New Look, Immunity, vol.14, issue.6, pp.661-664, 2001.
DOI : 10.1016/S1074-7613(01)00154-6

W. Cao, L. Bover, M. Cho, X. Wen, S. Hanabuchi et al., Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction, The Journal of Experimental Medicine, vol.63, issue.7, pp.1603-1614, 2009.
DOI : 10.1038/nm1201-1339

W. Cao, D. B. Rosen, T. Ito, L. Bover, M. Bao et al., Plasmacytoid dendritic cell???specific receptor ILT7???Fc??RI?? inhibits Toll-like receptor???induced interferon production, The Journal of Experimental Medicine, vol.203, issue.6, pp.1399-1405, 2006.
DOI : 10.1038/nbt836

W. E. Carson, C. L. Shapiro, T. R. Crespin, L. M. Thornton, and B. L. Andersen, Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment, Clinical Cancer Research, vol.10, issue.10, pp.3401-3409, 2004.
DOI : 10.1158/1078-0432.CCR-1016-03

D. Chauhan, A. V. Singh, M. Brahmandam, R. Carrasco, M. Bandi et al., Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target, Cancer Cell, vol.16, issue.4, pp.309-323, 2009.
DOI : 10.1016/j.ccr.2009.08.019

N. Contractor, J. Louten, L. Kim, C. A. Biron, and B. L. Kelsall, Cutting Edge: Peyer's Patch Plasmacytoid Dendritic Cells (pDCs) Produce Low Levels of Type I Interferons: Possible Role for IL-10, TGF??, and Prostaglandin E2 in Conditioning a Unique Mucosal pDC Phenotype, The Journal of Immunology, vol.179, issue.5, pp.2690-2694, 2007.
DOI : 10.4049/jimmunol.179.5.2690

J. Crawford, D. C. Dale, L. , and G. H. , Chemotherapy-induced neutropenia, Cancer, vol.112, issue.2, pp.228-237, 2004.
DOI : 10.1002/cncr.11882

T. J. Curiel, P. Cheng, P. Mottram, X. Alvarez, L. Moons et al., Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer, Cancer Research, vol.64, issue.16, pp.5535-5538, 2004.
DOI : 10.1158/0008-5472.CAN-04-1272

S. Demaria, M. D. Volm, R. L. Shapiro, H. T. Yee, R. Oratz et al., Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, Clin Cancer Res, vol.7, pp.3025-3030, 2001.

S. M. Dillon, K. B. Robertson, S. C. Pan, S. Mawhinney, A. L. Meditz et al., Plasmacytoid and Myeloid Dendritic Cells With a Partial Activation Phenotype Accumulate in Lymphoid Tissue During Asymptomatic Chronic HIV-1 Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.48, issue.1, pp.1-12, 2008.
DOI : 10.1097/QAI.0b013e3181664b60

C. Domschke, F. Schuetz, Y. Ge, T. Seibel, C. Falk et al., Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis, Cancer Research, vol.69, issue.21, pp.8420-8428, 2009.
DOI : 10.1158/0008-5472.CAN-09-1627

H. Donaghy, A. Pozniak, B. Gazzard, N. Qazi, J. Gilmour et al., Loss of blood CD11c+ myeloid and CD11c- plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load, Blood, vol.98, issue.8, pp.2574-2576, 2001.
DOI : 10.1182/blood.V98.8.2574

G. P. Dunn, A. T. Bruce, K. C. Sheehan, V. Shankaran, R. Uppaluri et al., A critical function for type I interferons in cancer immunoediting, Nature Immunology, vol.92, issue.7, pp.722-729, 2005.
DOI : 10.1146/annurev.immunol.21.120601 .141007

G. P. Dunn, C. M. Koebel, and R. D. Schreiber, Interferons, immunity and cancer immunoediting, Nature Reviews Immunology, vol.313, issue.11, pp.836-848, 2006.
DOI : 10.1038/nri1961

O. Duramad, K. L. Fearon, J. H. Chan, H. Kanzler, J. D. Marshall et al., IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences, Blood, vol.102, issue.13, pp.4487-4492, 2003.
DOI : 10.1182/blood-2003-07-2465

A. Dzionek, Y. Sohma, J. Nagafune, M. Cella, M. Colonna et al., BDCA-2, a Novel Plasmacytoid Dendritic Cell???specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon ??/?? Induction, The Journal of Experimental Medicine, vol.147, issue.12, pp.1823-1834, 2001.
DOI : 10.1016/S0167-5699(00)01745-X

N. Einhorn, K. Cantell, S. Einhorn, and H. Strander, Human leukocyte interferon therapy for advanced ovarian carcinoma, American Journal of Clinical Oncology, vol.5, issue.2, pp.167-172, 1982.
DOI : 10.1097/00000421-198204000-00064

L. B. Epstein, J. T. Shen, J. S. Abele, R. , and C. C. , SENSITIVITY OF HUMAN OVARIAN CARCINOMA CELLS TO INTERFERON AND OTHER ANTITUMOR AGENTS AS ASSESSED BY AN IN VITRO SEMI-SOLID AGAR TECHNIQUE, Annals of the New York Academy of Sciences, vol.62, issue.1 Regulatory Fu, pp.228-244, 1980.
DOI : 10.1038/277221a0

S. E. Erdman and T. Poutahidis, Roles for Inflammation and Regulatory T Cells in Colon Cancer, Toxicologic Pathology, vol.38, issue.1, pp.76-87
DOI : 10.1177/0192623309354110

D. Fabricius, M. Neubauer, B. Mandel, C. Schutz, A. Viardot et al., Prostaglandin E2 Inhibits IFN-?? Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement, The Journal of Immunology, vol.184, issue.2, pp.677-684
DOI : 10.4049/jimmunol.0902028

Q. M. Feng, W. Di, and X. Wu, [Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy], Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol.25, pp.1023-1025, 2009.

F. A. Fitzpatrick, W. , and R. , The immunopharmacology of paclitaxel (Taxol??), docetaxel (Taxotere??), and related agents, International Immunopharmacology, vol.3, issue.13-14, pp.1699-1714, 2003.
DOI : 10.1016/j.intimp.2003.08.007

D. Ganguly, G. Chamilos, R. Lande, J. Gregorio, S. Meller et al., Self-RNA???antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8, The Journal of Experimental Medicine, vol.161, issue.9, 1983.
DOI : 10.1038/nm1616

Q. Gao, S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang et al., Intratumoral Balance of Regulatory and Cytotoxic T Cells Is Associated With Prognosis of Hepatocellular Carcinoma After Resection, Journal of Clinical Oncology, vol.25, issue.18, pp.2586-2593, 2007.
DOI : 10.1200/JCO.2006.09.4565

C. T. Garnett, J. Schlom, H. , and J. W. , Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement, Clinical Cancer Research, vol.14, issue.11, pp.3536-3544, 2008.
DOI : 10.1158/1078-0432.CCR-07-4025

N. Giuliani, P. Storti, M. Bolzoni, B. D. Palma, and S. Bonomini, Angiogenesis and Multiple Myeloma, Cancer Microenvironment, vol.113, issue.1 Pt 1
DOI : 10.1007/s12307-011-0072-9

M. Gobert, Le cancer du sein, un environnement immunotolérant : émergence, mécanismes d'action des lymphocytes T régulateurs CD4+ CD25+ et relations avec les cellules dendritiques plasmacytoïdes, 2008.

M. Gobert, I. Treilleux, N. Bendriss-vermare, T. Bachelot, S. Goddard-leon et al., Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, Cancer Research, vol.69, issue.5, 2000.
DOI : 10.1158/0008-5472.CAN-08-2360

A. Golding, A. Rosen, M. Petri, E. Akhter, and F. Andrade, Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses, Immunology, vol.19, issue.Pt 1, pp.107-117
DOI : 10.1111/j.1365-2567.2010.03280.x

Z. Grossman, M. Meier-schellersheim, W. E. Paul, and L. J. Picker, Pathogenesis of HIV infection: what the virus spares is as important as what it destroys, Nature Medicine, vol.168, issue.3, pp.289-295, 2006.
DOI : 10.1038/nm1380

L. A. Hefler, R. Zeillinger, C. Grimm, A. K. Sood, W. F. Cheng et al., Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer, Gynecologic Oncology, vol.103, issue.2, pp.512-517, 2006.
DOI : 10.1016/j.ygyno.2006.03.058

N. Hiraoka, K. Onozato, T. Kosuge, and S. Hirohashi, Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions, Clinical Cancer Research, vol.12, issue.18, pp.5423-5434, 2006.
DOI : 10.1158/1078-0432.CCR-06-0369

I. Hirsch, C. Caux, U. Hasan, N. Bendriss-vermare, and D. Olive, Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer, Trends in Immunology, vol.31, issue.10, pp.391-397
DOI : 10.1016/j.it.2010.07.004

V. Hirsh, L. Paz-ares, M. Boyer, R. Rosell, G. Middleton et al., Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.29, issue.19, pp.2667-2674
DOI : 10.1200/JCO.2010.32.8971

K. Honda, H. Yanai, H. Negishi, M. Asagiri, M. Sato et al., IRF-7 is the master regulator of type-I interferon-dependent immune responses, Nature, vol.171, issue.7034, pp.772-777, 2005.
DOI : 10.1038/ni978

S. Hori, T. Nomura, and S. Sakaguchi, Control of Regulatory T Cell Development by the Transcription Factor Foxp3, Science, vol.299, issue.5609, pp.1057-1061, 2003.
DOI : 10.1126/science.1079490

T. Ito, M. Yang, Y. H. Wang, R. Lande, J. Gregorio et al., Plasmacytoid dendritic cells prime IL-10???producing T regulatory cells by inducible costimulator ligand, The Journal of Experimental Medicine, vol.157, issue.1, pp.105-115, 2007.
DOI : 10.1084/jem.20052359

J. J. Kiladjian, R. A. Mesa, and R. Hoffman, The renaissance of interferon therapy for the treatment of myeloid malignancies, Blood, vol.117, issue.18, pp.4706-4715
DOI : 10.1182/blood-2010-08-258772

M. S. Killian, S. H. Fujimura, F. M. Hecht, and J. A. Levy, Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment, AIDS, vol.20, issue.9, pp.1247-1252, 2006.
DOI : 10.1097/01.aids.0000232231.34253.bd

J. Kirkwood, Cancer immunotherapy: The interferon-?? experience, Seminars in Oncology, vol.29, issue.3, pp.18-26, 2002.
DOI : 10.1053/sonc.2002.33078

H. Kono, R. , and K. L. , How dying cells alert the immune system to danger, Nature Reviews Immunology, vol.171, issue.4, pp.279-289, 2008.
DOI : 10.1038/nri2215

A. M. Krieg, Therapeutic potential of Toll-like receptor 9 activation, Nature Reviews Drug Discovery, vol.34, issue.6, pp.471-484, 2006.
DOI : 10.1038/nrd2059

A. Krug, S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell et al., Identification of CpG oligonucleotide sequences with high induction of IFN-??/?? in plasmacytoid dendritic cells, European Journal of Immunology, vol.150, issue.7, pp.2154-2163, 2001.
DOI : 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U

S. I. Labidi-galy, V. Sisirak, P. Meeus, M. Gobert, I. Treilleux et al., Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer, Cancer Research, vol.71, issue.16
DOI : 10.1158/0008-5472.CAN-11-0367
URL : https://hal.archives-ouvertes.fr/hal-00849783

S. I. Labidi-galy, I. Treilleux, A. Bajard, O. Tredan, P. Meeus et al., Lymphopenia is an independent prognostic factor in ovarian cancer and could be associated with immune activation Paper presented at, ESMO annual meeting, 2011.

R. Lande, J. Gregorio, V. Facchinetti, B. Chatterjee, Y. H. Wang et al., Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide, Nature, vol.7, issue.7162, pp.564-569, 2007.
DOI : 10.1038/nature06116

N. Leffers, M. J. Gooden, R. A. De-jong, B. N. Hoogeboom, K. A. Ten-hoor et al., Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer, Cancer Immunology, Immunotherapy, vol.348, issue.3, pp.449-459, 2009.
DOI : 10.1007/s00262-008-0583-5

L. Li, S. Liu, T. Zhang, W. Pan, X. Yang et al., Splenic Stromal Microenvironment Negatively Regulates Virus-Activated Plasmacytoid Dendritic Cells through TGF-??, The Journal of Immunology, vol.180, issue.5, pp.2951-2956, 2008.
DOI : 10.4049/jimmunol.180.5.2951

W. Liu, A. L. Putnam, Z. Xu-yu, G. L. Szot, M. R. Lee et al., T reg cells, The Journal of Experimental Medicine, vol.376, issue.7, pp.1701-1711, 2006.
DOI : 10.1016/S0092-8674(04)00127-8

S. Z. Manrique, M. A. Correa, D. B. Hoelzinger, A. L. Dominguez, N. Mirza et al., Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth, The Journal of Experimental Medicine, vol.208, issue.12, pp.1485-1499
DOI : 10.1084/jem.2010073020812r

F. Martin, S. Ladoire, G. Mignot, L. Apetoh, and F. Ghiringhelli, Human FOXP3 and cancer, Oncogene, vol.129, issue.29, pp.4121-4129
DOI : 10.1038/onc.2010.174

C. Menetrier-caux, M. Gobert, C. , and C. , Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome, Cancer Research, vol.69, issue.20, pp.7895-7898, 2009.
DOI : 10.1158/0008-5472.CAN-09-1642

J. H. Meyers, J. S. Justement, C. W. Hallahan, E. T. Blair, Y. A. Sun et al., Impact of HIV on Cell Survival and Antiviral Activity of Plasmacytoid Dendritic Cells, PLoS ONE, vol.84, issue.5, p.458, 2007.
DOI : 10.1371/journal.pone.0000458.s001

K. Milne, M. Kobel, S. E. Kalloger, R. O. Barnes, D. Gao et al., Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors, PLoS ONE, vol.67, issue.7, p.6412, 2009.
DOI : 10.1371/journal.pone.0006412.t003

E. A. Moseman, X. Liang, A. J. Dawson, A. Panoskaltsis-mortari, A. M. Krieg et al., Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells, The Journal of Immunology, vol.173, issue.7, pp.4433-4442, 2004.
DOI : 10.4049/jimmunol.173.7.4433

L. Moserle, S. Indraccolo, M. Ghisi, C. Frasson, E. Fortunato et al., The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-?? Antitumor Effects, Cancer Research, vol.68, issue.14, pp.5658-5668, 2008.
DOI : 10.1158/0008-5472.CAN-07-6341

C. Napoletano, F. Bellati, R. Landi, S. Pauselli, C. Marchetti et al., Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression, Journal of Cellular and Molecular Medicine, vol.178, issue.12, pp.2748-2759
DOI : 10.1111/j.1582-4934.2009.00911.x

B. H. Nelson, The impact of T-cell immunity on ovarian cancer outcomes, Immunological Reviews, vol.16, issue.1, pp.101-116, 2008.
DOI : 10.1158/0008-5472.CAN-07-0565

O. 'keeffe, M. Grumont, R. J. Hochrein, H. Fuchsberger, M. Gugasyan et al., Distinct roles for the NF-??B1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals, Blood, vol.106, issue.10, pp.3457-3464, 2005.
DOI : 10.1182/blood-2004-12-4965

J. Pacanowski, S. Kahi, M. Baillet, P. Lebon, C. Deveau et al., Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection, Blood, vol.98, issue.10, pp.3016-3021, 2001.
DOI : 10.1182/blood.V98.10.3016

L. Pace, S. Vitale, B. Dettori, C. Palombi, L. Sorsa et al., APC Activation by IFN-?? Decreases Regulatory T Cell and Enhances Th Cell Functions, The Journal of Immunology, vol.184, issue.11, pp.5969-5979
DOI : 10.4049/jimmunol.0900526

A. K. Palucka, J. P. Blanck, L. Bennett, V. Pascual, and J. Banchereau, Cross-regulation of TNF and IFN-?? in autoimmune diseases, Proceedings of the National Academy of Sciences, vol.102, issue.9, pp.3372-3377, 2005.
DOI : 10.1073/pnas.0408506102

I. Perrot, D. Blanchard, N. Freymond, S. Isaac, B. Guibert et al., Dendritic Cells Infiltrating Human Non-Small Cell Lung Cancer Are Blocked at Immature Stage, The Journal of Immunology, vol.178, issue.5, pp.2763-2769, 2007.
DOI : 10.4049/jimmunol.178.5.2763

K. Riesbeck, Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes, Anti-Cancer Drugs, vol.10, issue.2, pp.219-227, 1999.
DOI : 10.1097/00001813-199902000-00011

P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps et al., T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.2, pp.186-192, 2009.
DOI : 10.1200/JCO.2008.18.7229

E. Sato, S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proceedings of the National Academy of Sciences, vol.102, issue.51, pp.18538-18543, 2005.
DOI : 10.1073/pnas.0509182102

B. Schmidt, S. H. Fujimura, J. N. Martin, and J. A. Levy, Variations in Plasmacytoid Dendritic Cell (PDC) and Myeloid Dendritic Cell (MDC) Levels in HIV-Infected Subjects on and off Antiretroviral Therapy, Journal of Clinical Immunology, vol.22, issue.2, pp.55-64, 2006.
DOI : 10.1007/s10875-006-8401-3

M. Schnurr, T. Toy, A. Shin, G. Hartmann, S. Rothenfusser et al., Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells, Blood, vol.103, issue.4, pp.1391-1397, 2004.
DOI : 10.1182/blood-2003-06-1959

T. Intratumoral, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer, Gynecol Oncol, vol.109, pp.215-219

M. D. Sharma, B. Baban, P. Chandler, D. Y. Hou, N. Singh et al., Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase, Journal of Clinical Investigation, vol.117, issue.9, pp.2570-2582, 2007.
DOI : 10.1172/JCI31911DS1

Y. Shi, J. E. Evans, R. , and K. L. , Molecular identification of a danger signal that alerts the immune system to dying cells, Nature, vol.425, issue.6957, pp.516-521, 2003.
DOI : 10.1038/nature01991

A. Shin, T. Toy, S. Rothenfusser, N. Robson, J. Vorac et al., P2Y receptor signaling regulates phenotype and IFN-?? secretion of human plasmacytoid dendritic cells, Blood, vol.111, issue.6, pp.3062-3069, 2008.
DOI : 10.1182/blood-2007-02-071910

V. Sisirak, G. M. Renaudineau, S. Menetrier-caux, C. Aspord, C. Banchereau et al., Breast carcinoma environment inhibits human plasmacytoid dendritic cells functions, the 10th international symposium on dendritic cells, 2008.

Y. Son, T. Ito, Y. Ozaki, T. Tanijiri, T. Yokoi et al., Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells, Immunology, vol.170, issue.1, pp.36-42, 2006.
DOI : 10.1189/jlb.1103534

V. Soumelis, I. Scott, F. Gheyas, D. Bouhour, G. Cozon et al., Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients, Blood, vol.98, issue.4, pp.906-912, 2001.
DOI : 10.1182/blood.V98.4.906

V. Tjomsland, P. Sandstrom, A. Spangeus, D. Messmer, J. Emilsson et al., Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity?, BMC Cancer, vol.223, issue.Suppl 7
DOI : 10.1097/00000658-199603000-00007

M. L. Tsiatas, R. Gyftaki, C. Liacos, E. Politi, A. Rodolakis et al., Study of T Lymphocytes Infiltrating Peritoneal Metastases in Advanced Ovarian Cancer, International Journal of Gynecological Cancer, vol.12, issue.8, pp.1329-1334, 2009.
DOI : 10.1111/IGC.0b013e3181b7a40e

S. Wei, I. Kryczek, L. Zou, B. Daniel, P. Cheng et al., Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma, Cancer Research, vol.65, issue.12, pp.5020-5026, 2005.
DOI : 10.1158/0008-5472.CAN-04-4043

L. M. Williams and A. Y. Rudensky, Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3, Nature Immunology, vol.2, issue.3, pp.277-284, 2007.
DOI : 10.1189/jlb.0605342

Y. Yokoyama, D. S. Charnock-jones, D. Licence, A. Yanaihara, J. M. Hastings et al., Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma, British Journal of Cancer, vol.88, issue.2, pp.237-244, 2003.
DOI : 10.1038/sj.bjc.6600701

H. Y. Zhang and H. Sun, Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer, Cancer Letters, vol.287, issue.1, pp.91-97
DOI : 10.1016/j.canlet.2009.06.001

L. Zhou, M. M. Chong, and D. R. Littman, Plasticity of CD4+ T Cell Lineage Differentiation, Immunity, vol.30, issue.5, pp.646-655, 2009.
DOI : 10.1016/j.immuni.2009.05.001

L. Zitvogel, A. Tesniere, and G. Kroemer, Cancer despite immunosurveillance: immunoselection and immunosubversion, Nature Reviews Immunology, vol.65, issue.10, pp.715-742, 2006.
DOI : 10.1038/nri1936

R. Schreiber, L. Old, and M. Smyth, Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-70, 2011.
DOI : 10.1126/science.1203486

L. Zhang, J. Conejo-garcia, and D. Katsaros, Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer, New England Journal of Medicine, vol.348, issue.3, pp.203-216, 2003.
DOI : 10.1056/NEJMoa020177

T. Curiel, G. Coukos, and L. Zou, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nature Medicine, vol.165, issue.9, pp.942-951, 2004.
DOI : 10.1016/S0022-1759(01)00359-3

E. Sato, S. Olson, and J. Ahn, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proceedings of the National Academy of Sciences, vol.102, issue.51, pp.18538-18581, 2005.
DOI : 10.1073/pnas.0509182102

M. Raspollini, F. Castiglione, R. Degl-'innocenti, and D. , Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma, Annals of Oncology, vol.16, issue.4, pp.590-596, 2005.
DOI : 10.1093/annonc/mdi112

M. Tomsova, B. Melichar, I. Sedlakova, and I. Steiner, Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma, Gynecologic Oncology, vol.108, issue.2, pp.415-435, 2008.
DOI : 10.1016/j.ygyno.2007.10.016

J. Barnett, S. Bean, and R. Whitaker, Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype, Gynecologic Oncology, vol.116, issue.3, pp.556-62, 2010.
DOI : 10.1016/j.ygyno.2009.11.020

B. Clarke, A. Tinker, and C. Lee, Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss, Modern Pathology, vol.61, issue.3, pp.393-402, 2009.
DOI : 10.1038/sj.bjc.6602534

R. Giuntoli, T. Webb, and A. Zoso, Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity, Anticancer Res, vol.29, pp.2875-84, 2009.

A. Bamias, M. Tsiatas, and E. Kafantari, Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance, Gynecologic Oncology, vol.106, issue.1, pp.75-81, 2007.
DOI : 10.1016/j.ygyno.2007.02.029

Y. Miyahara, K. Odunsi, and W. Chen, Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer, Proceedings of the National Academy of Sciences, vol.105, issue.40, pp.15505-15515, 2008.
DOI : 10.1073/pnas.0710686105

I. Kryczek, M. Banerjee, and P. Cheng, Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments, Blood, vol.114, issue.6, pp.1141-1150, 2009.
DOI : 10.1182/blood-2009-03-208249

M. Levings, R. Sangregorio, and M. Roncarolo, T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function, The Journal of Experimental Medicine, vol.38, issue.11, pp.1295-302, 2001.
DOI : 10.1093/intimm/12.8.1145

M. Gobert, I. Treilleux, and N. Bendriss-vermare, Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, Cancer Research, vol.69, issue.5, pp.2000-2009, 2009.
DOI : 10.1158/0008-5472.CAN-08-2360

D. Wolf, A. Wolf, and H. Rumpold, The Expression of the Regulatory T Cell-Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer, Clinical Cancer Research, vol.11, issue.23, pp.8326-8357, 2005.
DOI : 10.1158/1078-0432.CCR-05-1244

N. Leffers, M. Gooden, and R. De-jong, Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer, Cancer Immunology, Immunotherapy, vol.348, issue.3, pp.449-59, 2009.
DOI : 10.1007/s00262-008-0583-5

F. Siegal, N. Kadowaki, and M. Shodell, The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood, Science, vol.284, issue.5421, pp.1835-1842, 1999.
DOI : 10.1126/science.284.5421.1835

M. Cella, D. Jarrossay, and F. Facchetti, Plasmacytoid monocytes migrate to infl amed lymph nodes and produce large amounts of type I interferon, Nat Med, vol.5, pp.919-942, 1999.

H. Yoneyama, S. Narumi, and Y. Zhang, Pivotal Role of Dendritic Cell???derived CXCL10 in the Retention of T Helper Cell 1 Lymphocytes in Secondary Lymph Nodes, The Journal of Experimental Medicine, vol.52, issue.10, pp.1257-66, 2002.
DOI : 10.1002/1521-4141(200201)32:1<231::AID-IMMU231>3.0.CO;2-8

W. Zou, V. Machelon, and A. Coulomb-l-'hermin, Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells, Nature Medicine, vol.7, issue.12, pp.1339-1385, 2001.
DOI : 10.1038/nm1201-1339

S. Wei, I. Kryczek, and L. Zou, Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma, Cancer Research, vol.65, issue.12, pp.5020-5026, 2005.
DOI : 10.1158/0008-5472.CAN-04-4043

T. Curiel, P. Cheng, and P. Mottram, Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer, Cancer Research, vol.64, issue.16, pp.5535-5543, 2004.
DOI : 10.1158/0008-5472.CAN-04-1272

S. Labidi-galy, V. Sisirak, and P. Meeus, Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer, Cancer Research, vol.71, issue.16, 2011.
DOI : 10.1158/0008-5472.CAN-11-0367
URL : https://hal.archives-ouvertes.fr/hal-00849783

V. Sisirak, J. Faget, and M. Gobert, TGF-b from breast tumor impairs innate immune response of plasmacytoid dendritic cells establishing immune tolerance through Treg expansion

I. Kryczek, S. Wei, and G. Zhu, Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma, Cancer Research, vol.67, issue.18, pp.8900-8905, 2007.
DOI : 10.1158/0008-5472.CAN-07-1866

A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy, European Journal of Cancer, vol.42, issue.6, pp.717-744, 2006.
DOI : 10.1016/j.ejca.2006.01.003

C. Tempfer, H. Zeisler, and G. Sliutz, Serum Evaluation of Interleukin 6 in Ovarian Cancer Patients, Gynecologic Oncology, vol.66, issue.1, pp.27-30, 1997.
DOI : 10.1006/gyno.1997.4726

G. Gastl, M. Plante, and C. Finstad, High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer, British Journal of Haematology, vol.165, issue.3, pp.433-474, 1993.
DOI : 10.1016/S0140-6736(86)92192-6

A. Li, A. Madden, and I. Cass, The prognostic significance of thrombocytosis in epithelial ovarian carcinoma, Gynecologic Oncology, vol.92, issue.1, pp.211-214, 2004.
DOI : 10.1016/j.ygyno.2003.09.002

R. Garg, M. Wollan, and V. Galic, Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma, Gynecologic Oncology, vol.103, issue.3, pp.793-799, 2006.
DOI : 10.1016/j.ygyno.2006.08.043

G. Rodriguez, C. Haisley, and J. Hurteau, Regulation of Invasion of Epithelial Ovarian Cancer by Transforming Growth Factor-??, Gynecologic Oncology, vol.80, issue.2, pp.245-53, 2001.
DOI : 10.1006/gyno.2000.6042

C. Marth, H. Fiegl, and A. Zeimet, Interferon-?? expression is an independent prognostic factor in ovarian cancer, American Journal of Obstetrics and Gynecology, vol.191, issue.5, pp.1598-605, 2004.
DOI : 10.1016/j.ajog.2004.05.007

T. Kusuda, K. Shigemasa, and K. Arihiro, Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer, Oncology Reports, vol.13, pp.1153-1161, 2005.
DOI : 10.3892/or.13.6.1153

J. Akahiro, R. Konno, and K. Ito, Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma, International Journal of Clinical Oncology, vol.9, issue.1, pp.42-48, 2004.
DOI : 10.1007/s10147-003-0360-6

L. Epstein, J. Shen, J. Abele, and C. Reese, SENSITIVITY OF HUMAN OVARIAN CARCINOMA CELLS TO INTERFERON AND OTHER ANTITUMOR AGENTS AS ASSESSED BY AN IN VITRO SEMI-SOLID AGAR TECHNIQUE, Annals of the New York Academy of Sciences, vol.62, issue.1 Regulatory Fu, pp.228-272, 1980.
DOI : 10.1038/277221a0

A. Zeimet, M. Widschwendter, and C. Knabbe, Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer., Journal of Clinical Oncology, vol.16, issue.5, pp.1861-1869, 1998.
DOI : 10.1200/JCO.1998.16.5.1861

E. Gorelik, D. Landsittel, and A. Marrangoni, Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.4, pp.981-988, 2005.
DOI : 10.1158/1055-9965.EPI-04-0404

A. Lambeck, A. Crijns, and N. Leffers, Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7, Clinical Cancer Research, vol.13, issue.8, pp.2385-91, 2007.
DOI : 10.1158/1078-0432.CCR-06-1828

B. Li, A. Lalani, and T. Harding, Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF-Secreting Cancer Immunotherapy, Clinical Cancer Research, vol.12, issue.22, pp.6808-6824, 2006.
DOI : 10.1158/1078-0432.CCR-06-1558

L. Hefl-er, R. Zeillinger, and C. Grimm, Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer, Gynecologic Oncology, vol.103, issue.2, pp.512-519, 2006.
DOI : 10.1016/j.ygyno.2006.03.058

A. Bamias, V. Koutsoukou, and E. Terpos, Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNF?? in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy, Gynecologic Oncology, vol.108, issue.2, pp.421-428, 2008.
DOI : 10.1016/j.ygyno.2007.10.018

X. Xie, D. Ye, and H. Chen, Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma, International Journal of Gynecology & Obstetrics, vol.85, pp.151-159, 2004.
DOI : 10.1016/S0020-7292(03)00437-5

C. Borg, I. Ray-coquard, and I. Philip, CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer, Cancer, vol.52, issue.11, pp.2675-80, 2004.
DOI : 10.1002/cncr.20688

I. Ray-coquard, C. Cropet, and M. Van-glabbeke, Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas, Cancer Research, vol.69, issue.13, pp.5383-91, 2009.
DOI : 10.1158/0008-5472.CAN-08-3845

S. Bishara, M. Griffi-n, and A. Cargill, Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.138, issue.1, pp.71-75, 2008.
DOI : 10.1016/j.ejogrb.2007.05.012

H. Cho, H. Hur, and S. Kim, Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment, Cancer Immunology, Immunotherapy, vol.23, issue.25, pp.15-23, 2009.
DOI : 10.1007/s00262-008-0516-3

B. Liu, J. Nash, and C. Runowicz, Ovarian cancer immunotherapy: opportunities, progresses and challenges, Journal of Hematology & Oncology, vol.3, issue.1, p.7, 2010.
DOI : 10.1186/1756-8722-3-7

K. Schmeler, S. Vadhan-raj, and P. Ramirez, A phase II study of GM-CSF and rIFN-??1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer, Gynecologic Oncology, vol.113, issue.2, pp.210-215, 2009.
DOI : 10.1016/j.ygyno.2009.02.007

P. Brossart, S. Wirths, and G. Stuhler, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, vol.96, pp.3102-3110, 2000.

F. Hodi, M. Butler, and D. Oble, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Proceedings of the National Academy of Sciences, vol.105, issue.8, pp.3005-3015, 2008.
DOI : 10.1073/pnas.0712237105

Y. Nesbeth, U. Scarlett, and J. Cubillos-ruiz, CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion, Cancer Research, vol.69, issue.15, pp.6331-6339, 2009.
DOI : 10.1158/0008-5472.CAN-08-4329
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755640

B. Barnett, I. Kryczek, and P. Cheng, Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential, American Journal of Reproductive Immunology, vol.168, issue.6, pp.369-377, 2005.
DOI : 10.1038/ni904

P. Hwu, Treating Cancer by Targeting the Immune System, New England Journal of Medicine, vol.363, issue.8, pp.779-81, 2010.
DOI : 10.1056/NEJMe1006416

F. Hodi, O. Day, S. Mcdermott, and D. , Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466